Article Versions Notes

Garcha HK, Nawar N, Sorger H, Erdogan F, Aung MMK, Sedighi A, Manaswiyoungkul P, Seo H-S, Schönefeldt S, Pölöske D, et al. High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma. Pharmaceuticals. 2022; 15(11):1321. https://doi.org/10.3390/ph15111321

Garcha, Harsimran Kaur, Nabanita Nawar, Helena Sorger, Fettah Erdogan, Myint Myat Khine Aung, Abootaleb Sedighi, Pimyupa Manaswiyoungkul, Hyuk-Soo Seo, Susann Schönefeldt, Daniel Pölöske, and et al. 2022. "High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma" Pharmaceuticals 15, no. 11: 1321. https://doi.org/10.3390/ph15111321

Garcha, H. K., Nawar, N., Sorger, H., Erdogan, F., Aung, M. M. K., Sedighi, A., Manaswiyoungkul, P., Seo, H. -S., Schönefeldt, S., Pölöske, D., Dhe-Paganon, S., Neubauer, H. A., Mustjoki, S. M., Herling, M., de Araujo, E. D., Moriggl, R., & Gunning, P. T. (2022). High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma. Pharmaceuticals, 15(11), 1321. https://doi.org/10.3390/ph15111321